Jonathan Fuller, DO
Family Medicine · Gadsden, ALNPI 1013315001
Payments from drug & device makers
Across 101 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$398
- GSK$386
- Novo Nordisk$160
- Abbott$121
- Pfizer$104
- AbbVie$84
- plus $474 from 16 others
What the payments were for
- Food & beverage$1,728100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $398 |
| GSK | 27 | $386 |
| Novo Nordisk | 10 | $160 |
| Abbott | 6 | $121 |
| Pfizer | 7 | $104 |
| AbbVie | 5 | $84 |
| Boehringer Ingelheim | 4 | $71 |
| Lilly USA, LLC | 5 | $71 |
| Johnson & Johnson | 4 | $67 |
| Astellas Pharma US Inc | 2 | $46 |
| Amgen | 2 | $39 |
| Novartis | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 2 | $17 |
| IBSA Pharma Inc. | 1 | $16 |
| Exact Sciences | 1 | $14 |
| Bayer | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$1,728 in reported general payments places this provider in the 65th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 383 | $476,720 |
| MounjaroTirzepatide | 339 | $425,712 |
| EliquisApixaban | 174 | $188,609 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $178,876 |
| JardianceEmpagliflozin | 98 | $127,192 |
| TrulicityDulaglutide | 72 | $113,559 |
| XareltoRivaroxaban | 94 | $95,795 |
| JanuviaSitagliptin Phosphate | 79 | $77,275 |
| LinzessLinaclotide | 58 | $61,820 |
| FarxigaDapagliflozin Propanediol | 55 | $61,367 |
| MyrbetriqMirabegron | 68 | $55,493 |
| RybelsusSemaglutide | 38 | $50,368 |
| EntrestoSacubitril/Valsartan | 32 | $37,650 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $24,443 |
| VascepaIcosapent Ethyl | 49 | $22,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $71 | $539,271411 claims |
| Novo NordiskOzempic, Rybelsus | $160 | $527,088421 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $386 | $223,375224 claims |
| PfizerEliquis | $104 | $188,609174 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $71 | $141,829111 claims |
| Johnson & JohnsonXarelto | $67 | $95,79594 claims |
| MerckJanuvia | $12 | $77,27579 claims |
| AbbVieLinzess, Savella | $84 | $68,06371 claims |
| AstraZenecaFarxiga | $398 | $61,36755 claims |
| Astellas Pharma US IncMyrbetriq | $46 | $55,49368 claims |
| NovartisEntresto | $28 | $37,65032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Gadsden
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.